New BioSource Kit Tracks Infection From Transplants

A Camarillo company has released the first commercially available kit that helps track the severity of infections in organ transplant, cancer and AIDS patients.

BioSource International will market the ViralQuant-CMV kit to antiviral drug programs and clinical researchers.

“We are very excited about both the immediate and long-term market potential for ViralQuant-CMV and the confirmation of our strategy to leverage the company’s test kit design and development expertise to enter the emerging market for molecular diagnostic products,” said James H. Chamberlain, chief executive officer of BioSource.

The company believes the product may eventually be an effective tool in helping to treat infections in thousands of transplant patients annually. About 45% of people with acquired immune deficiency also suffer from the cytomegalovirus infections that the kit is designed to measure.

BioSource International supplies more than 1,300 products used in biomedical research. Last year the company, which is traded on Nasdaq, reported earnings of $2,767,198, or $0.35 per share, on revenues of $15,913,274.